Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Mingozzi

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Diabetes|February 5, 2013
Treatment of diabetes and long-term survival after insulin and glucokinase gene therapyDavid Callejas, Christopher J Mann, Eduard Ayuso, et al.
Scientific Reports|January 23, 2020
Capsid-specific removal of circulating antibodies to adeno-associated virus vectorsBerangere Bertin, Philippe Veron, Christian Leborgne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 20, 2020
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia BLindsey A George, Margaret V Ragni, John E J Rasko, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2020
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-GlucosidaseUmut Cagin, Francesco Puzzo, Manuel Jose Gomez, et al.
Blood Advances|January 4, 2018
Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectorsAmine Meliani, Florence Boisgerault, Zachary Fitzpatrick, et al.
Blood|March 26, 2010
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia BValder R Arruda, Hansell H Stedman, Virginia Haurigot, et al.
Molecular Metabolism|February 12, 2024
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapySergio Muñoz, Joan Bertolin, Veronica Jimenez, et al.
Science Translational Medicine|July 19, 2013
Overcoming preexisting humoral immunity to AAV using capsid decoysFederico Mingozzi, Xavier M Anguela, Giulia Pavani, et al.
The New England Journal of Medicine|August 16, 2023
Gene Therapy in Patients with the Crigler-Najjar SyndromeLorenzo D'Antiga, Ulrich Beuers, Giuseppe Ronzitti, et al.
Nature Communications|October 7, 2018
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administrationAmine Meliani, Florence Boisgerault, Romain Hardet, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Diabetes|February 5, 2013
Treatment of diabetes and long-term survival after insulin and glucokinase gene therapyDavid Callejas, Christopher J Mann, Eduard Ayuso, et al.
Scientific Reports|January 23, 2020
Capsid-specific removal of circulating antibodies to adeno-associated virus vectorsBerangere Bertin, Philippe Veron, Christian Leborgne, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 20, 2020
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia BLindsey A George, Margaret V Ragni, John E J Rasko, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 12, 2020
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-GlucosidaseUmut Cagin, Francesco Puzzo, Manuel Jose Gomez, et al.
Blood Advances|January 4, 2018
Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectorsAmine Meliani, Florence Boisgerault, Zachary Fitzpatrick, et al.
Blood|March 26, 2010
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia BValder R Arruda, Hansell H Stedman, Virginia Haurigot, et al.
Molecular Metabolism|February 12, 2024
Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapySergio Muñoz, Joan Bertolin, Veronica Jimenez, et al.
Science Translational Medicine|July 19, 2013
Overcoming preexisting humoral immunity to AAV using capsid decoysFederico Mingozzi, Xavier M Anguela, Giulia Pavani, et al.
The New England Journal of Medicine|August 16, 2023
Gene Therapy in Patients with the Crigler-Najjar SyndromeLorenzo D'Antiga, Ulrich Beuers, Giuseppe Ronzitti, et al.
Nature Communications|October 7, 2018
Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administrationAmine Meliani, Florence Boisgerault, Romain Hardet, et al.
Pageof 14